Longitudinal surveillance of bacteraemia in haematology and oncology patients at a uk cancer centre and the impact of ciprofloxacin use on antimicrobial resistance

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1431-1438

  Schelenz, S ^a,b   Nwaka, D ^a   Hunter, P R ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Antimicrobial resistance; Bloodstream infections; Cancer; Immunosuppression

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; FLUCONAZOLE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER INFECTION; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANAEROBE; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS; BACTEREMIA; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CAMPYLOBACTER; CAMPYLOBACTERIOSIS; CANCER CENTER; CANCER PATIENT; CANDIDA ALBICANS; CANDIDIASIS; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORYNEBACTERIUM; CORYNEBACTERIUM INFECTION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE SURVEILLANCE; DRUG USE; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; GROUP B STREPTOCOCCAL INFECTION; HAEMOPHILUS; HAEMOPHILUS INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; KLEBSIELLA; KLEBSIELLA INFECTION; LISTERIA MONOCYTOGENES; LISTERIOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MYCOBACTERIOSIS; MYCOBACTERIUM; PASTEURELLA; PASTEURELLOSIS; PNEUMOCOCCAL INFECTION; PRESCRIPTION; PROPIONIBACTERIUM; PROTEUS; PROTEUS INFECTION; PSEUDOMONAS; PSEUDOMONAS INFECTION; SALMONELLA; SALMONELLOSIS; SERRATIA; SERRATIA INFECTION; SOLID TUMOR; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS VIRIDANS INFECTION; TREND STUDY; UNITED KINGDOM; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTIMICROBIAL RESISTANCE; BLOODSTREAM INFECTIONS; CANCER; IMMUNOSUPPRESSION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CANCER CARE FACILITIES; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GREAT BRITAIN; HEMATOLOGIC NEOPLASMS; LONGITUDINAL STUDIES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MONITORING, PHYSIOLOGIC; NEOPLASMS; ORGANIZATIONAL POLICY; STREPTOCOCCAL INFECTIONS;

EID: 84885194222     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt002     Document Type: Article

References (34)

1. Danai PA, Moss M, Mannino DM et al. The epidemiology of sepsis in patients with malignancy. Chest 2006; 129: 1432-40.
2. Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004; 8: R291-8.
3. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-4.
4. Elting LS, Bodey GP, Keefe BH. Septicaemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-7.
5. Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010; 116: 967-73.
6. Gomez L,GarauJ, Estrada Cet al. Ciprofloxacin prophylaxis in patientswith acute leukaemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003; 97: 419-23.
7. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95.
8. Safdar A, Rolston K. Stenotrophomonas maltophilia: changing spectrum of serious bacterial pathogens in patients with cancer. Clin Infect Dis 2007; 45: 1602-9.
9. HPA. Access to UK Standards for Microbiology Investigations. www.hpa. org.uk/ProductsServices/MicrobiologyPathology (7 August 2012, date last accessed).
10. BSAC. Breakpoints. http://bsac.org.uk/wp-content/uploads/2012/02/Version-11.1-2012- Final-1.pdf (7 August 2012, date last accessed).
11. WHO. Guideline for ATC Classification and DDD Assignment, 15th edn. http://www.whocc.no/filearchive/publications/2012_guidelines/_with_ front_pa.pdf (12 February 2012, date last accessed).
12. Anon. Multicollinearity. http://www.nd.edu/~rwilliam/stats2/l11.pdf (26 October 2012, date last accessed).
13. CancerStats: Cancer Statistics for the UK. http://www.cancerresearchuk. org/cancer-info/cancerstats/ (23 July 2012, date last accessed).
14. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
15. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
16. Yadegarynia D, Tarrand J, Raad I, et al. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37: 1144-5.
17. Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol 2012; 23: 1889-93.
18. Del Favero A, Menichetti F, Martino P, et al. A multicentre, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-301.
19. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
20. Pratt RJ, Pellowe CM, Wilson JA, et al. epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2007; 65 Suppl 1: S1-64.
21. Tumbarello M, Spanu T, Caira M, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 2009; 64: 320-6.
22. Cherif H, Kronvall G, Bjorkholm M, et al. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 2003; 4: 420-6.
23. Han XY, Kamana M, Rolston KVI. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 2006; 44: 160-5.
24. Pan A, Carnevale G, Catenazzi P, et al. Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA. Infect Control Hosp Epidemiol 2005; 26: 127-33.
25. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 2009; 48 Suppl 4: S231-7.
26. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
27. Jugo J, Kennedy R, Crowe MJ, et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect 2002; 50: 48-55.
28. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrugresistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66: 657-63.
29. Jones RN. Contemporary antimicrobial susceptible patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: 495-502.
30. Frère P, Hermanne JP, Debouge MH, et al. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2002; 29: 589-94.
31. Kern WV, Steib-Bauert M, deWith K, et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005; 55: 57-60.
32. Zemkova M, Kotlarova J, Merka V, et al. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the Department of Clinical Hematology. New Microbiol 2007; 30: 423-30.
33. NICE. Clinical Guideline 151. September 2012. Guidance.nice.org.uk/ cg151 (1 November 2012, date last accessed).
34. Prentice HG, Hann IM, Nazareth B, et al. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol 2001; 115: 46-52.